Literature DB >> 25074677

Heat inactivation of the Middle East respiratory syndrome coronavirus.

India Leclercq1, Christophe Batéjat, Ana M Burguière, Jean-Claude Manuguerra.   

Abstract

The culture supernatants of the emerging Middle East respiratory syndrome coronavirus (MERS-CoV) were submitted to three temperatures over time and tested for infectivity by TCID50 method on Vero E6 cells. At 56°C, almost 25 minutes were necessary to reduce the initial titre by 4 log10 . Increasing temperature to 65°C had a strong negative effect on viral infectivity as virucidy dropped significantly to 1 minute. On the contrary, no significant decrease in titre was observed after 2 hours at 25°C. These data might be useful in establishing biosafety measures in laboratories against MERS-CoV.
© 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Heat; MERS-CoV; inactivation

Mesh:

Year:  2014        PMID: 25074677      PMCID: PMC4181824          DOI: 10.1111/irv.12261

Source DB:  PubMed          Journal:  Influenza Other Respir Viruses        ISSN: 1750-2640            Impact factor:   4.380


Short report

The emerging Middle East respiratory syndrome coronavirus (MERS-CoV) was found to cause sporadic cases of severe acute respiratory infection. Between April 2012 and 26 April 2014, a total of 261 laboratory-confirmed cases of infection with MERS-CoV were reported, including 93 deaths, in nine different countries.1 To date, the viral transmission route is still not elucidated, although recent studies showed that tomb bats and camels may play a role as reservoirs or intermediate hosts.2,3 Coronaviruses are enveloped viruses, usually known to be fragile in the environment. However, enveloped viruses can persist in the environment for extended periods of time, even at 35°C.4 Understanding the potential effect of heat inactivation of the novel coronavirus is of significant value to elaborate proper public intervention measures. A human strain of MERS-CoV was isolated in our laboratory from a French patient hospitalised in June 2013 after a nosocomial transmission.5 The viral strain MERS-CoV Hu/France–FRA2_130569/2013 (FRA2) was grown on MRC5 cells (RD-Biotech REF-84002) for the first passage and on Vero E6 cells (ATCC® CRL-1586) for the second passage. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM 1X, GIBCO; Invitrogen, Saint Aubin, France) and supplemented with 5% foetal calf serum (FCS), antibiotics (0·1 units penicillin, 0·1 mg streptomycin per ml, GIBCO; Invitrogen) at 37°C in humidified 5% CO2 incubator. The cell culture supernatant was used for inactivation assays and whole-genome sequencing (manuscript under submission). Culture supernatants (500 μl) with a titre of 105·59 TCID50 per ml were submitted to three temperatures over time and tested for infectivity by TCID50 method on Vero E6 cells as described previously, except that examination for cytopathic effect was performed after 6 days.4 Several time points were chosen (0, 0·5, 15, 30, 60 and 120 minutes). Each condition was performed in triplicates, and the whole experiment was accomplished twice. Experimental data from one experiment are shown in Table1. For each condition, we determined the virucidal activity of heat at 56 and 65°C, which corresponded to a reduction of 4 log10 of the titre according to the European Standards (NF EN 14476 available at http://www.afnor.org/; Table2). At 56°C, which is the common temperature used for inactivation of enveloped viruses, such as influenza viruses, and serum decomplementation, almost 25 minutes were necessary to reduce the initial titre by 4 log10. Increasing temperature to 65°C had a strong negative effect on viral infectivity as virucidy dropped significantly to 1 minute. Fifteen minutes at 65°C is more than sufficient to totally inactivate the sample. By contrast, no decrease in titre was observed after 2 hours at 25°C.
Table 1

TCID50 per ml values obtained at 56 and 65°C

56°C65°C


Time (minute)0·51530601200·5153060120
Sample 1105·5100·67NDNDND104·67NDNDNDND
Sample 2106·17101·0100·67NDND102·00NDNDNDND
Sample 3104·67ND101·33ND100·67103·67NDNDNDND

Time zero values were 105·59 TCID50 per ml for each sample. ND: not detected (below the limit of virus detection which corresponded to 100·67 TCID50 per ml). The whole experiment was performed twice with similar results (data not shown).

Table 2

Persistence times estimated using linear regression model for heat inactivation at 25, 56 and 65°C

StrainTemperatureSlope (a)y-Intercept (b)x-Intercept (minute)Virucidy (minute)
FRA225°C0·0065·25NANA
56°C−0·165·0930·7 [26·0; 35·2]24·1
65°C−3·625·251·45 [1·0; 1·9]1·1

Slope (a), y-intercept (b) and x-intercept values of the linear regression straight lines calculated from TCID50 values (ND values in Table1 were not included in the calculation). Virucidy corresponded to the duration necessary to obtain a fourfold reduction of the titre in log10. The values in brackets corresponded to the 99% confidence intervals. NA, not applicable. Each condition was performed in triplicates. The whole experiment was performed twice with similar results (data not shown).

TCID50 per ml values obtained at 56 and 65°C Time zero values were 105·59 TCID50 per ml for each sample. ND: not detected (below the limit of virus detection which corresponded to 100·67 TCID50 per ml). The whole experiment was performed twice with similar results (data not shown). Persistence times estimated using linear regression model for heat inactivation at 25, 56 and 65°C Slope (a), y-intercept (b) and x-intercept values of the linear regression straight lines calculated from TCID50 values (ND values in Table1 were not included in the calculation). Virucidy corresponded to the duration necessary to obtain a fourfold reduction of the titre in log10. The values in brackets corresponded to the 99% confidence intervals. NA, not applicable. Each condition was performed in triplicates. The whole experiment was performed twice with similar results (data not shown). Serum heat inactivation at 56°C for 30 minutes is a standard procedure in diagnostic laboratories to eliminate the potential complement interference in serological assays. Our results showed that this procedure is sufficient for viral inactivation as virus titres in blood are expected to be weaker than at the point of infection. This would be also sufficient for inactivation of viruses present in lower respiratory specimens, which are now recommended by WHO rather than nasopharyngeal swabs for viral diagnosis. For example, the FRA2 original clinical specimen (induced sputum) contained 6·5 × 107 genome copies per ml for Orf1a calculated from the C values using a standard (manuscript under submission). These data might be also useful in establishing biosafety measures in laboratories against MERS-CoV.
  4 in total

1.  Persistence of the 2009 pandemic influenza A (H1N1) virus in water and on non-porous surface.

Authors:  Amélie Dublineau; Christophe Batéjat; Anthony Pinon; Ana Maria Burguière; India Leclercq; Jean-Claude Manuguerra
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

2.  Middle East respiratory syndrome coronavirus in bats, Saudi Arabia.

Authors:  Ziad A Memish; Nischay Mishra; Kevin J Olival; Shamsudeen F Fagbo; Vishal Kapoor; Jonathan H Epstein; Rafat Alhakeem; Abdulkareem Durosinloun; Mushabab Al Asmari; Ariful Islam; Amit Kapoor; Thomas Briese; Peter Daszak; Abdullah A Al Rabeeah; W Ian Lipkin
Journal:  Emerg Infect Dis       Date:  2013-11       Impact factor: 6.883

3.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study.

Authors:  Chantal B E M Reusken; Bart L Haagmans; Marcel A Müller; Carlos Gutierrez; Gert-Jan Godeke; Benjamin Meyer; Doreen Muth; V Stalin Raj; Laura Smits-De Vries; Victor M Corman; Jan-Felix Drexler; Saskia L Smits; Yasmin E El Tahir; Rita De Sousa; Janko van Beek; Norbert Nowotny; Kees van Maanen; Ezequiel Hidalgo-Hermoso; Berend-Jan Bosch; Peter Rottier; Albert Osterhaus; Christian Gortázar-Schmidt; Christian Drosten; Marion P G Koopmans
Journal:  Lancet Infect Dis       Date:  2013-08-09       Impact factor: 25.071

4.  Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission.

Authors:  Benoit Guery; Julien Poissy; Loubna el Mansouf; Caroline Séjourné; Nicolas Ettahar; Xavier Lemaire; Fanny Vuotto; Anne Goffard; Sylvie Behillil; Vincent Enouf; Valérie Caro; Alexandra Mailles; Didier Che; Jean-Claude Manuguerra; Daniel Mathieu; Arnaud Fontanet; Sylvie van der Werf
Journal:  Lancet       Date:  2013-05-30       Impact factor: 79.321

  4 in total
  55 in total

1.  Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2.

Authors:  Sharon Unger; Natasha Christie-Holmes; Furkan Guvenc; Patrick Budylowski; Samira Mubareka; Scott D Gray-Owen; Deborah L O'Connor
Journal:  CMAJ       Date:  2020-07-09       Impact factor: 8.262

Review 2.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3. 

Authors:  Sharon Unger; Natasha Christie-Holmes; Furkan Guvenc; Patrick Budylowski; Samira Mubareka; Scott D Gray-Owen; Deborah L O'Connor
Journal:  CMAJ       Date:  2020-11-30       Impact factor: 8.262

Review 4.  Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: A review.

Authors:  Hamada A Aboubakr; Tamer A Sharafeldin; Sagar M Goyal
Journal:  Transbound Emerg Dis       Date:  2020-07-14       Impact factor: 4.521

5.  Inactivation and safety testing of Middle East Respiratory Syndrome Coronavirus.

Authors:  Mia Kumar; Steven Mazur; Britini L Ork; Elena Postnikova; Lisa E Hensley; Peter B Jahrling; Reed Johnson; Michael R Holbrook
Journal:  J Virol Methods       Date:  2015-07-17       Impact factor: 2.014

Review 6.  An Opportunistic Pathogen Afforded Ample Opportunities: Middle East Respiratory Syndrome Coronavirus.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Viruses       Date:  2017-12-02       Impact factor: 5.048

7.  Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2.

Authors:  Xiumei Hu; Taixue An; Bo Situ; Yuhai Hu; Zihao Ou; Qiang Li; Xiaojing He; Ye Zhang; Peifu Tian; Dehua Sun; Yongyu Rui; Qian Wang; Dan Ding; Lei Zheng
Journal:  J Clin Lab Anal       Date:  2020-06-28       Impact factor: 2.352

Review 8.  Monitoring of new coronavirus (SARS-CoV-2): Origin, transmission, and food preservation methods.

Authors:  Reza Farahmandfar; Maryam Asnaashari; Bakhtiyar Hesami
Journal:  J Food Process Preserv       Date:  2021-06-12       Impact factor: 2.609

9.  Selection of parameters for thermal coronavirus inactivation - a data-based recommendation.

Authors:  Martin Hessling; Katharina Hoenes; Christian Lingenfelder
Journal:  GMS Hyg Infect Control       Date:  2020-07-13

Review 10.  Environmental and decontamination issues for human coronaviruses and their potential surrogates.

Authors:  Nevio Cimolai
Journal:  J Med Virol       Date:  2020-07-02       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.